The inhibition of FAK blocks tumor proliferation and prolongs the survival in a c-Met/β-catenin-driven hepatocellular carcinoma (HCC) mouse model [104], suggesting that inhibition of FAK might be beneficial for treating HCC, especially in patients showing activated β-catenin. Here, MET is linked to neoplasm.